乐鱼在线
乐鱼在线:About Henlius
乐鱼在线:Company Profile
Corporate Culture
Honor
Board of Directors
乐鱼在线:Management Team
Advisory Committee
Product
乐鱼在线:Marketed Products
乐鱼在线:Products in R&D
Clinical Trial
Science & Technology
乐鱼在线:R&D Result
乐鱼在线:Innovation Centre
乐鱼在线:Technology Platform
乐鱼在线:Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
乐鱼在线:Stock Info
IR Calendar
Investor Presentation
乐鱼在线:Analyst Coverage
乐鱼在线:Contact Information
Media
Press Release
乐鱼在线:Multi-media
乐鱼在线:Media Reports
乐鱼在线:Media Enquiry
Careers
Talent Philosophy
Staff Life
乐鱼在线:Training and Development
乐鱼在线:Contact Us
乐鱼在线:Contact Information
乐鱼在线:Customer Message
Privacy
乐鱼在线:Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
乐鱼在线:Board of Directors
乐鱼在线:Management Team
乐鱼在线:Advisory Committee
Product
乐鱼在线:Marketed Products
乐鱼在线:Products in R&D
乐鱼在线:Clinical Trial
Science & Technology
乐鱼在线:R&D Result
乐鱼在线:Innovation Centre
Technology Platform
乐鱼在线:Quality Management
乐鱼在线:Manufacturing
Collaborations
乐鱼在线:Investor Relations
Information Disclosure
乐鱼在线:Listing Documents
乐鱼在线:Announcement & Circulars
Corporate Governance
乐鱼在线:Financial Reports
乐鱼在线:Stock Info
IR Calendar
乐鱼在线:Investor Presentation
乐鱼在线:Analyst Coverage
Contact Information
Media
Press Release
2022
2021
2020
2019
2018
2017
2016
2015
2014
乐鱼在线:Multi-media
Company
Event
Popular Science
Media Reports
乐鱼在线:Media Enquiry
Careers
Talent Philosophy
Staff Life
乐鱼在线:Training and Development
乐鱼在线:Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2023-12-28
HANSIZHUANG Sets Sail in Indonesia Market
2023-12-27
FDA Grants Fast Track Designation to Henlius’ EGFR-Targeting ADC HLX42 for NSCLC Patients with Disease Progression on EGFR Targeted Therapies
2023-12-22
Henlius Passes Its Second EU GMP Inspection
2023-12-13
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Ipilimumab Biosimilar HLX13
2023-12-12
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
2023-12-05
Henlius Receives "Listed Enterprises 2023" Award from Bloomberg Businessweek/Chinese Edition
2023-12-04
Results from Four Phase 1/2 Clinical Trials of Henlius’ Innovative Products Released at 2023 ESMO Asia
2023-12-04
Results from the Phase 2 Clinical Trial of Henlius BRAF Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ESMO Asia
2023-12-04
Results of the Asian Subgroup in Phase 3 Clinical Study of Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at ESMO Asia 2023
1
2
3
...
8
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
乐鱼在线官网-乐鱼在线
ufc下注官网_ufc竞猜平台【新版本下载】
ufc下注_ufc押注网站
ufc下注官网_ufc竞猜软件【注册登录】
天博APP-天博APP下载-天博APP官方网站